Pulmonx Corporation (LUNG)
| Market Cap | 53.64M -64.6% |
| Revenue (ttm) | 88.55M +1.2% |
| Net Income | -53.21M |
| EPS | -1.29 |
| Shares Out | 42.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,275 |
| Open | 1.330 |
| Previous Close | 1.340 |
| Day's Range | 1.250 - 1.330 |
| 52-Week Range | 1.130 - 3.880 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 5.38 (+323.62%) |
| Earnings Date | Apr 29, 2026 |
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult... [Read more]
Financial Performance
In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $5.38, which is an increase of 323.62% from the latest price.
News
Pulmonx Transcript: Bank of America Global Healthcare Conference 2026
A minimally invasive valve system for severe emphysema has shown strong clinical results and high reimbursement rates, with global reach and a $12 billion addressable market. Recent pipeline expansion and financial restructuring aim to drive renewed growth.
Pulmonx reports Q1 EPS (33c), consensus (33c)
Reports Q1 revenue $20.59M, consensus $20.43M. “During the first quarter we initiated our refreshed U.S. commercial strategies and continued to execute in our direct international markets. We are enco...
Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M
The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company continues to expect…
Pulmonx Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined 9% year-over-year to $20.6 million, with U.S. and international sales both down due to China registration delays, but excluding China, international markets grew 22%. Cost reductions, a new credit facility, and a focused sales strategy support reaffirmed 2026 guidance and expectations for double-digit growth exiting the year.
Pulmonx Reports First Quarter 2026 Financial Results
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today repor...
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the co...
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will...
Pulmonx price target lowered to $5 from $6 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Pulmonx (LUNG) to $5 from $6 and keeps a Buy rating on the shares. The firm said Q4 results came…
Pulmonx reports Q4 EPS (25c), consensus (38c)
Reports Q4 revenue $22.6M, consensus $21.73M. “While our recent performance reflects a period of transition, we see a substantial opportunity to rebuild momentum through a clear operating plan focused...
Pulmonx sees FY26 revenue $90M-$92M, consensus $94.23M
The company said, “Pulmonx (LUNG) expects revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company expects gross margin for the…
Pulmonx Earnings Call Transcript: Q4 2025
Revenue grew 8% in 2025 to $90.5M, but U.S. sales declined in Q4 due to internal challenges and high sales force turnover. Cost restructuring and debt refinancing improved financial flexibility, with double-digit growth expected by Q4 2026.
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today repor...
Pulmonx Announces Closing of up to $60 Million Credit Facility
Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providi...
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx reports Q3 EPS (34c), consensus (42c)
Reports Q3 revenue $21.5M, consensus $20.9M. “While our third quarter performance broadly met expectations, we feel there is a meaningful opportunity to leverage our operational foundation and refine ...
Pulmonx cuts FY25 revenue view to $89M-$90M from $90M-$92M
Consensus $90.69M. The company said, “Pulmonx (LUNG) is updating its 2025 financial outlook and expects full year 2025 total revenue to be in the range of $89 million to $90…
Pulmonx Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 5% year-over-year to $21.5M, with international markets outpacing the U.S. Operating expenses and net loss remained high, but leadership is focused on realigning spending and improving profitability. Full-year revenue guidance is $89M-$90M.
Pulmonx Reports Third Quarter 2025 Financial Results
REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
Pulmonx price target lowered to $4 from $8 at Lake Street
Lake Street lowered the firm’s price target on Pulmonx (LUNG) to $4 from $8 and keeps a Buy rating on the shares. While the return of former CEO Glen French…
Pulmonx CEO Steve Williamson resigns, Glen French succeeds
Pulmonx (LUNG) announced the reappointment of Glen French as president and CEO, effective immediately, and the appointment of Derrick Sung as COO and CFO, effective November 3. Concurrently, Steve Wil...
Pulmonx reports preliminary Q3 revenue $21.5M, consensus $20.78M
The company said, “The Company plans to provide further details on its third quarter results and full year outlook during its third quarter 2025 earnings call rescheduled for November 12,…
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx files $200M mixed securities shelf
17:20 EDT Pulmonx (LUNG) files $200M mixed securities shelf